Acid ceramidase as a therapeutic target in metastatic prostate cancer

Luz Camacho, Óscar Meca‐Cortés, José Luı́s Abad, Simón García, Núria Rubio, Alba Díaz, Toni Celià-Terrassa, Francesca Cingolani, Raquel Bermudo, Pedro L. Fernández,

Journal of Lipid Research · 2013 · 72 citations · 30 references

DOIFull text

Open access

Concepts

Abstract

Acid ceramidase (AC) catalyzes the hydrolysis of ceramide into sphingosine, in turn a substrate of sphingosine kinases that catalyze its conversion into the mitogenic sphingosine-1-phosphate. AC is expressed at high levels in several tumor types and has been proposed as a cancer therapeutic target. Using a model derived from PC-3 prostate cancer cells, the highly tumorigenic, metastatic, and chemoresistant clone PC-3/Mc expressed higher levels of the AC ASAH1 than the nonmetastatic clone PC-3/S. Stable knockdown of ASAH1 in PC-3/Mc cells caused an accumulation of ceramides, inhibition of clonogenic potential, increased requirement for growth factors, and inhibition of tumorigenesis and lung metastases. We developed de novo ASAH1 inhibitors, which also caused a dose-dependent accumulation of ceramides in PC-3/Mc cells and inhibited their growth and clonogenicity. Finally, immunohistochemical analysis of primary prostate cancer samples showed that higher levels of ASAH1 were associated with more advanced stages of this neoplasia. These observations confirm ASAH1 as a therapeutic target in advanced and chemoresistant forms of prostate cancer and suggest that our new potent and specific AC inhibitors could act by counteracting critical growth properties of these highly aggressive tumor cells. Acid ceramidase (AC) catalyzes the hydrolysis of ceramide into sphingosine, in turn a substrate of sphingosine kinases that catalyze its conversion into the mitogenic sphingosine-1-phosphate. AC is expressed at high levels in several tumor types and has been proposed as a cancer therapeutic target. Using a model derived from PC-3 prostate cancer cells, the highly tumorigenic, metastatic, and chemoresistant clone PC-3/Mc expressed higher levels of the AC ASAH1 than the nonmetastatic clone PC-3/S. Stable knockdown of ASAH1 in PC-3/Mc cells caused an accumulation of ceramides, inhibition of clonogenic potential, increased requirement for growth factors, and inhibition of tumorigenesis and lung metastases. We developed de novo ASAH1 inhibitors, which also caused a dose-dependent accumulation of ceramides in PC-3/Mc cells and inhibited their growth and clonogenicity. Finally, immunohistochemical analysis of primary prostate cancer samples showed that higher levels of ASAH1 were associated with more advanced stages of this neoplasia. These observations confirm ASAH1 as a therapeutic target in advanced and chemoresistant forms of prostate cancer and suggest that our new potent and specific AC inhibitors could act by counteracting critical growth properties of these highly aggressive tumor cells. Cancer cells develop a lipogenic phenotype that supports the energy and membrane synthesis requirements associated with the enhanced proliferation and survival under stress inherent to malignant progression (1Hirsch H.A. Iliopoulos D. Joshi A. Zhang Y. Jaeger S.A. Bulyk M. Tsichlis P.N. Shirley Liu X. Struhl K. A transcriptional signature and common gene networks link cancer with lipid metabolism and diverse human diseases.Cancer Cell. 2010; 17: 348-361Abstract Full Text Full Text PDF PubMed Scopus (270) Google Scholar, 2Menendez J.A. Lupu R. Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis.Nat. Rev. Cancer. 2007; 7: 763-777Crossref PubMed Scopus (2024) Google Scholar). The recognition of the importance of this phenotype in cancer has led to the use of enzymes of lipid metabolism as markers to monitor neoplastic progression and response to therapy, as well as to the development of drugs targeted at key lipogenic enzymes, such as fatty acid synthase (FASN) (2Menendez J.A. Lupu R. Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis.Nat. Rev. Cancer. 2007; 7: 763-777Crossref PubMed Scopus (2024) Google Scholar, 3Mashima T. Seimiya H. Tsuruo T. De novo fatty-acid synthesis and related pathways as molecular targets for cancer therapy.Br. J. Cancer. 2009; 100: 1369-1372Crossref PubMed Scopus (385) Google Scholar). The excess fatty acid synthesis that results from the coordinated activation of lipogenic enzymes in many types of cancer leads to the accumulation of palmitate, which needs to be further processed by the cells due to the toxic effects of its accumulation. One pathway that many neoplastic cells activate to offset the toxic accumulation of palmitate is its peroxisome proliferator-activated receptor (PPAR)γ-dependent funneling to eventually form triglycerides, which can be further used as energy stores (4Kourtidis A. Srinivasaiah R. Carkner R.D. Brosnan M.J. Conklin D.S. Peroxisome proliferator-activated receptor-gamma protects ERBB2-positive breast cancer cells from palmitate toxicity.Breast Cancer Res. 2009; 11: R16Crossref PubMed Scopus (48) Google Scholar). A second pathway followed by palmitate is the condensation of palmitoyl CoA with L-serine, leading to the synthesis of ceramides (5Delgado A. Casas J. Llebaria A. Abad J.L. Fabrias G. Inhibitors of sphingolipid metabolism enzymes.Biochim. Biophys. Acta. 2006; 1758: 1957-1977Crossref PubMed Scopus (144) Google Scholar). The accumulation of ceramides also poses a problem for cell survival because of its proapoptotic consequences (6Kolesnick R.N. Kronke M. Regulation of ceramide production and apoptosis.Annu. Rev. Physiol. 1998; 60: 643-665Crossref PubMed Scopus (728) Google Scholar, 7Hannun Y.A. Obeid L.M. Ceramide: an intracellular signal for apoptosis.Trends Biochem. Sci. 1995; 20: 73-77Abstract Full Text PDF PubMed Scopus (573) Google Scholar, 8Ogretmen B. Hannun Y.A. Biologically active sphingolipids in cancer pathogenesis and treatment.Nat. Rev. Cancer. 2004; 4: 604-616Crossref PubMed Scopus (1006) Google Scholar). This can be counteracted by activities that convert ceramides to a variety of metabolites, including sphingosines through deacylation catalyzed by ceramidases. Sphingosines can be converted into the growth- and survival-promoting sphingosine-1-phosphate (S1P) through the action of sphingosine kinases (8Ogretmen B. Hannun Y.A. Biologically active sphingolipids in cancer pathogenesis and treatment.Nat. Rev. Cancer. 2004; 4: 604-616Crossref PubMed Scopus (1006) Google Scholar). S1P can be either irreversibly degraded by S1P lyase or reutilized by sequential dephosphorylation and acylation for ceramide synthesis. The importance of ceramidases in the context of cancer is supported by the observation that their inhibition by drugs or RNAi severely compromises the growth and survival under stress of tumor cells (9Liu X. Elojeimy S. Turner L.S. Mahdy A.E. Zeidan Y.H. Bielawska A. Bielawski J. Dong J.Y. El-Zawahry A.M. Guo G.W. et al.Acid ceramidase inhibition: a novel target for cancer therapy.Front. Biosci. 2008; 13: 2293-2298Crossref PubMed Scopus (53) Google Scholar). De novo ceramide biosynthesis requires the coordinate action of serine palmitoyl transferase and ceramide synthase to generate ceramide. This process begins with the condensation of serine and palmitoyl-CoA to form 3-ketosphinganine (5Delgado A. Casas J. Llebaria A. Abad J.L. Fabrias G. Inhibitors of sphingolipid metabolism enzymes.Biochim. Biophys. Acta. 2006; 1758: 1957-1977Crossref PubMed Scopus (144) Google Scholar), which is reduced to the sphingoid base sphinganine and acylated by ceramide synthase to generate dihydroceramide. This compound is oxidized to ceramide by introduction of a trans-4,5 double bond. This pathway can be stimulated by drugs and ionizing radiation and usually results in a prolonged ceramide accumulation (10Henry, B., Moller, C., Dimanche-Boitrel, M. T., Gulbins, E., Becker, K. A., . Targeting the ceramide system in cancer. Cancer Lett., Epub ahead of print. July 23, 2011; doi:10.1016/j.canlet.2011.07.010.Google Scholar). Once generated, ceramide may amass or be converted into a variety of metabolites. Phosphorylation by ceramide kinase (11Bornancin F. Ceramide kinase: the first 2011; PubMed Scopus Google ceramide deacylation by or acid ceramidases of A. Casas J. Fabrias G. Abad J.L. A. et of metabolism and of in Res. 2010; PubMed Scopus Google sphingosine, which may be by sphingosine kinase to sphingosine kinases been These in of expressed in and properties Regulation of sphingosine kinase and sphingolipid Biochem. Sci. 2011; Full Text Full Text PDF PubMed Scopus Google Scholar), that Ceramide may also be converted to by of from and of the synthase 2010; PubMed Scopus Google Scholar). can be by synthase to form which may be further by enzymes in the to form T. and 2009; PubMed Scopus Google Scholar). tumor types high levels of acid ceramidase the levels of AC in prostate cancer been to be to prostate Bielawska A. T. A. S. Hannun Y. D. M. S. et therapeutic use of and inhibitors of ceramide metabolism in prostate and and a 2006; 13: PubMed Scopus (53) Google Scholar, A. Liu acid ceramidase is in prostate Cancer. PubMed Scopus Google Scholar). cancer is the in in J. of cancer and in in J. Cancer. 2010; Full Text Full Text PDF PubMed Scopus Google Scholar). is to and a of eventually to such therapeutic with aggressive of and that highly to D. the development of prostate Cancer Res. 2006; PubMed Scopus Google Scholar, A. A. de The therapeutic of prostate Rev. 2011; PubMed Scopus Google Scholar). in to markers that to a aggressive as to and to molecular targets for of that to new to the that the acid ceramidase ASAH1 is a therapeutic target in advanced prostate and new potent and specific inhibitors of PC-3/Mc and cells T. F. de A.M. A. R. A. M. et can of human PubMed Scopus Google were in with and from from a and to AC were in a at in as cells were at a of cells in were with the specific or cells were either processed or by with and were at with ceramidase the of by with in cells. were by with in and by in an the of for acid ceramidase substrate Abad J.L. Fabrias G. T. A for of acid ceramidase and of Res. 2010; Full Text Full Text PDF PubMed Scopus Google or with of the cell of and at for of were for and with of The by of followed by in at of were and at a ceramidase in cells, were in The by substrate for at in a and the as in by a of the substrate for Biochem. PubMed Scopus Google Scholar). The of with and of substrate in of in and of or at and used as of inhibition of The by the of of and the at The of a system to a of in Full from to were and were to and were by an by the The a The were also A as at The at the of by and of and with that of a These were in an system to a with an The of a of and the at were at the were and by and to membrane with in were with primary with or and were by were used as and with the were with the were a and with the The levels of and were used as to the levels of specific and by the were in were in with in and at for at by of cells were with and with A at for and in a and cell with were in in at the of to and with a of cells in in were with a were with with and under a to an were with the of in to cells with were in a of of in of growth by an of in of lung cells in were through the were and tumor development by to from with tumor cells and to the lung survival that an increased were as the and or were from The cell with these with and for were for the and through were by at for were with and to the cells with were for and to in for for cells with for in with to cells at a of at for and the were with at a A of the acid and in to a sphinganine in or The for at and at reduced The in with and the to a that by a of to the in for the The of human with and requirements by the were for either from and or from with a A of prostate and were were and used for immunohistochemical the were at for in and primary for at used at a of as the of cells with and the were with an with an by the the The PC-3 prostate cancer cell used to generate cells were in by from PC-3 cells. A second from cells, a PC-3 that been in for its high T. F. de A.M. A. R. A. M. et can of human PubMed Scopus Google Scholar). in of PC-3/Mc cells with the of by in of T. F. de A.M. A. R. A. M. et can of human PubMed Scopus Google Scholar). PC-3/Mc cells than cells PC-3/Mc cells were highly cells showed growth the sphingolipid of cell cells were and under and their sphingolipid of analysis showed that ceramide in cells that of PC-3/Mc cells this increased to for the and PC-3/Mc the cell of and ceramide including and higher in cells than in PC-3/Mc cells and this for the and were the cell showed that the highly aggressive and PC-3/Mc cells levels of AC that were to higher than of cells, either in cell at or in cells a Abad J.L. Fabrias G. T. A for of acid ceramidase and of Res. 2010; Full Text Full Text PDF PubMed Scopus Google Scholar). that the of the ceramidase in these cells is due to the were by ceramidase by ceramidases which is a substrate of of by PC-3/Mc cells. the in these cells with which AC PC-3/Mc cells expressed to higher levels of the AC ASAH1 than cells, as by A showed that the in ASAH1 and levels were by at the a of ASAH1 the ceramidase and of ASAH1 and nonmetastatic prostate cancer cell and to its importance for the growth and properties of PC-3/Mc cells, to its were with the ASAH1 of these were at ASAH1 levels with from to This gene knockdown by a inhibition of the AC in these cells The of and were by The sphingolipid of PC-3/Mc cells by caused the accumulation of ceramides, and with cells with a an of ceramide which the of the sphingosine increased in knockdown which that ceramidases knockdown of ASAH1 R. Bielawski J. Obeid L.M. ceramidase ceramides, and its cell proliferation and 2010; Full Text Full Text PDF PubMed Scopus Google Scholar). We this accumulation of ceramides an of the growth or of PC-3/Mc cells. of the the PC-3/Mc the accumulation of that PC-3/Mc cells to the and effects of ceramide accumulation under growth the growth of PC-3/Mc cells in growth from that of cells at of at a of cells showed a reduced growth with cells This that ASAH1 be to cell including or to ASAH1 knockdown PC-3/Mc cells to of growth factors, their of proliferation in these PC-3/Mc cells at than cells at with more effects at the with the of ASAH1 knockdown the growth of PC-3/Mc cells in of the caused a of the with an increased The of cells to form in is a of their and is related to their and in Cancer cells in and Rev. Cancer. 2008; PubMed Scopus Google Scholar). the cells were as to the nonmetastatic cells. of ASAH1 the clonogenic of PC-3/Mc cells that ASAH1 is for their knockdown of ASAH1 inhibited the of PC-3/Mc cells to form in with of the and their to PC-3/Mc cells to the effects survival or the cell caused by ceramide accumulation knockdown of a ASAH1 for the of key properties associated with cells, growth in and tumorigenesis and lung in The results the importance of ASAH1 for the and of PC-3 prostate cancer cells, and as a therapeutic target in prostate cancer. AC inhibitors been and with in the that AC is a a of ceramide at the with and These were in inhibitors T. and their Rev. PubMed Scopus Google and and several as in The of by of were in cells as well as in cell at the Abad J.L. Fabrias G. T. A for of acid ceramidase and of Res. 2010; Full Text Full Text PDF PubMed Scopus Google Scholar, Casas J. T. Fabrias G. of a novel ceramide and its use in a for 2007; PubMed Scopus Google Scholar). The inhibitors in cells were and with of inhibition from to and their activities in the in in cell and were for further their the were for their effects the substrate M. S. M. and for and ceramidases Biochem. PubMed Scopus Google and cells with the of the inhibited to their as inhibitors of acid showed that the with an of followed by and which the in the of or the an at the an of inhibited the of the at the the at under which inhibited AC by the We the effects of and the growth properties of PC-3/Mc cells. the of these AC by the cells with for and AC in cell a these the inhibition of AC by and dose-dependent which to be a AC in cells and cell AC in PC-3/Mc cells. to the of AC in these cells We the for this in the effects of these cell or of the in the prostate cancer cell may to the The sphingolipid of PC-3/Mc cells with these their AC and an accumulation of ceramides as for its of AC in PC-3/Mc cells, the of The of sphingolipids such as or by of the for the levels of in cells with at which increased This is in with the of ASAH1 in PC-3/Mc cells, which caused the accumulation of these sphingolipids a second knockdown and inhibition of levels of sphingosine by of PC-3/Mc cells with either or increased ASAH1 We that prolonged knockdown of ASAH1 may an response of cells by ceramidases to the of the ceramides that as a of ASAH1 The inhibition of AC by inhibitors, such as in the to such These were for their effects the growth of PC-3/Mc cells. a of and in the growth of PC-3/Mc cells by the showed the growth at the AC inhibitors active PC-3/Mc cells, and the of PC-3/Mc cells to form in effects in these of the effects at a of and to knockdown of of the inhibitors caused in the cell of PC-3/Mc cells the dose-dependent of these PC-3/Mc cells The toxic compound followed by and a AC in PC-3/Mc cells, its these cells be caused by The nonmetastatic clone more to the effects of than were the PC-3/Mc cells, to and and The of these of cell with or including the prostate cells the lung cancer cell and the breast cancer cell The aggressive cell were more to the of these acid ceramidase inhibitors than were their more aggressive to ASAH1 of the developed AC inhibitors, and showed activities AC and the growth and clonogenic of the highly PC-3/Mc cells. growth effects PC-3/Mc cells, A which AC in cells, AC in PC-3/Mc cells, and these cells, potent the growth of these cells and showed their to in has been that ASAH1 is expressed in a of tumor including at levels higher than in A. Liu acid ceramidase is in prostate Cancer. PubMed Scopus Google Scholar). its in has been by which to of with We used an to by a of samples from prostate cancer that with and with of the prostate for at a of from to or neoplastic were an of of of and of and of with as of of and of of were as and in which and could be in the the ASAH1 of were as in the as in in and in the in as than the in and several the for ASAH1 in than the in ASAH1 in human prostate to be associated with prostate an observation that in which immunohistochemical analysis and the specific cell either or ASAH1 A. Liu acid ceramidase is in prostate Cancer. PubMed Scopus Google Scholar). the with the ASAH1 with or the of the observation that of ASAH1 associated with the more than with and in turn with prostate more than with that ASAH1 levels to prostate cancer a form of the that from aggressive and to J. of cancer and in in J. Cancer. 2010; Full Text Full Text PDF PubMed Scopus Google Scholar, D. the development of prostate Cancer Res. 2006; PubMed Scopus Google Scholar, A. A. de The therapeutic of prostate Rev. 2011; PubMed Scopus Google Scholar). this the in the tumor of cancer cells, with high survival and Cancer cells in and Rev. Cancer. 2008; PubMed Scopus Google Scholar, R. G.W. A. gene signature in aggressive human 2008; PubMed Scopus Google Scholar), is as the derived from prostate cancer cells and highly in cells T. F. de A.M. A. R. A. M. et can of human PubMed Scopus Google Scholar), and that its growth and clonogenic to the knockdown of ASAH1 or inhibition of AC knockdown of ASAH1 in these cells inhibited their to or to the growth of PC-3/Mc cells under also by ASAH1 of growth factors, that ASAH1 is for growth of PC-3/Mc cells under growth is for growth growth at high These with the phenotype that in growth which with tumorigenic, and T. F. de A.M. A. R. A. M. et can of human PubMed Scopus Google Scholar, Cancer cells in and Rev. Cancer. 2008; PubMed Scopus Google for ASAH1 knockdown and AC suggest that AC is for and growth in and PC-3/Mc prostate cancer cells. ASAH1 knockdown and inhibition of AC a specific a growth of PC-3/Mc cells, is further supported by the of cell or the accumulation of cell in of the accumulation of ASAH1 knockdown AC inhibition caused a of PC-3/Mc cells to drugs used in advanced prostate cancer therapy, including and which the of this highly aggressive of prostate cancer cells in cells by the accumulation of The of AC inhibition or ASAH1 knockdown to PC-3/Mc cells from the in tumor cells A. Bielawski J. Liu X. J. Hannun Y.A. Bielawska A. and of of 2009; 17: PubMed Scopus Google Scholar, Casas J. Fabrias G. T. Acid ceramidase the of cells to 2011; Full Text Full Text PDF PubMed Scopus Google Scholar, D. Hannun Y.A. of sphingolipid and J. 2011; PubMed Scopus Google Scholar, S. Liu X. A.M. El-Zawahry J.Y. A.E. Mahdy L.S. et of acid ceramidase in to therapeutic acid ceramidase inhibitors and gene 2007; Full Text Full Text PDF PubMed Scopus Google Scholar, M. Fabrias G. A. Casas J. Abad J.L. and targeted inhibition of acid ceramidase in breast cancer cell Cancer Res. PubMed Scopus Google Scholar, M. R. Fabrias G. A. Casas J. of acid ceramidase by a prostate cancer cells to 2011; PubMed Scopus Google Scholar, A.E. J. Elojeimy S. Turner L.S. A. et al.Acid ceramidase in prostate cancer cells to AC a 2009; 17: Full Text Full Text PDF PubMed Scopus Google Scholar, A. R. A. inhibition or acid ceramidase cells to and tumor growth in 2007; PubMed Scopus Google Scholar, G. D. A.M. Bielawska A. M.J. The ceramide in prostate cancer cell and tumor growth in prostate cancer 2004; PubMed Scopus Google Scholar, A. Bielawski J. Liu X. Hannun Y.A. Bielawska A. of and synthesis and as 2008; PubMed Scopus Google Scholar). PC-3/Mc cells, AC inhibition or ASAH1 knockdown may specific pathways to the ceramide pathways and conversion into The of as a tumor A. A. of ceramide and sphingosine in 2008; Google as in PC-3/Mc cells, of or and higher in cells than in cells. been as targets to S. T. Y. of ceramide as a for cancer PubMed Scopus Google Scholar, M. T. M. T. T. Y. K. M. T. T. of ceramide as an of of the ceramide activation of synthase and synthase in chemoresistant Cancer Res. Google Scholar), the of inhibition of as a to ceramide as an has been metabolism and in 2011; 11: PubMed Scopus Google Scholar, M. Y. of pathway in PubMed Scopus Google Scholar). is the of ceramide by also the increased been to the of through kinase and H. cancer cells and their in 2011; PubMed Scopus Google Scholar). ceramide or is ASAH1 in PC-3/Mc cells has been the levels higher in than in PC-3/Mc cells as to their AC the in and in PC-3/Mc cells for AC AC is a and ceramides from the M. M. K. A. S. S. R. T. ceramide is to the in to a 1998; PubMed Scopus Google Scholar), a of AC leads to an accumulation of ceramide. synthase is in the synthase and synthase in the and of the synthase 2010; PubMed Scopus Google Scholar, in 2010; PubMed Scopus Google Scholar). of this the in and is to from synthesis from the ceramide. A of acid and as a of ceramide the sphingolipid of the PC-3/Mc cells for AC is to that in cells. This supports that the accumulation of sphingolipids the as a of AC activities in is related to the of the The recognition of AC as a therapeutic target in cancer has the development of AC inhibitors A. Casas J. Fabrias G. Abad J.L. A. et of metabolism and of in Res. 2010; PubMed Scopus Google Scholar). AC to the X. R. and activation of human acid 2008; Full Text Full Text PDF PubMed Scopus Google Scholar). This of enzymes the common of an which is by J. of Sci. PubMed Scopus Google Scholar). The in AC is at the of the of the AC to the of as the this AC has been to be inhibited by the inhibitors, X. D. R. of as a novel of acid 2011; Full Text Full Text PDF PubMed Scopus Google Scholar). the of this novel potent and specific inhibitors of AC a of in inhibitors M. and to 2006; PubMed Scopus Google Scholar, R. Y. K. M. inhibitors and therapeutic 2006; 13: PubMed Scopus Google Scholar, R. as Rev. 2007; 7: PubMed Scopus Google Scholar). These either an or an The first in cells AC showed the the and were the potent the the AC activities in cells and cell of the active with their as The of the to suggest that at the the of the as AC the for this been is that the high of results in of the AC target. The of the is and the potent AC inhibitors D. A. R. T. D. of highly potent acid ceramidase inhibitors with in tumor PubMed Scopus Google Scholar), with of and as with of cells of inhibition supported that and inhibitors, which with the their and the of a in the and a their for and were also potent inhibitors of AC in PC-3/Mc cells. which inhibited AC in cells, to AC in the PC-3/Mc cell This is due to the to the of the their at with their AC and a of ceramides, which with for the levels of sphingosine The for AC inhibitors, Bielawska et A. Bielawski J. Liu X. A. Elojeimy S. B. J. et of and signature effects 2008; PubMed Scopus Google that the sphingolipid of cells with ceramidase inhibitors derived from and followed the for the the of an of compound ceramides A is the of to sphingolipids at One such could an increased of ceramidases. A to the of sphingosine in PC-3/Mc cells for of this et R. Bielawski J. Obeid L.M. ceramidase ceramides, and its cell proliferation and 2010; Full Text Full Text PDF PubMed Scopus Google that knockdown of the ceramidase the of the ceramidase with of sphingosine and its the that ceramidase metabolism Ceramide in cell and novel of a lipid and the of ceramide 2011; PubMed Google more acid ceramidase critical of the tumorigenic, and of cancer cells, by the PC-3/Mc T. F. de A.M. A. R. A. M. et can of human PubMed Scopus Google Scholar), their of that the cell survival and that our for with and aggressive to therapeutic advanced cancer H. cancer cells and their in 2011; PubMed Scopus Google Scholar). The the AC and the increased of PC-3/Mc cells with the clone is under The and for and for with and for for this and critical with with acid ceramidase ceramide ceramidase prostate cancer prostate sphingosine-1-phosphate

References

30